Prescription drug prices in the United States have decreased by 0.8% in July and are down 3.1% from the previous year, marking the steepest annual decline in over sixty years, according to the Consumer Price Index data from the Bureau of Labor Statistics. This decline is notable as it occurs amidst rising costs for hospital and physician services.
The Trump administration has claimed credit for this price drop, although the administration's TrumpRx website, which connects patients with discounted cash prices, likely only accounts for part of the decline. Pharmaceutical companies Eli Lilly and Novo Nordisk have also reached agreements with the administration that reduced prices for certain drugs and expanded Medicare access.
Additionally, Medicare negotiations established under the Inflation Reduction Act took effect in January for ten of the program's most expensive drugs, with negotiated prices reaching up to 79% below their list prices.
Experts suggest that while TrumpRx facilitates finding discounts, much of the price decline is driven by market forces. Geoffrey Joyce, a health economist at USC, indicated that the Inflation Reduction Act's impact is limited compared to existing market dynamics.
Despite the overall decline in drug prices, many Americans remain concerned about affordability. A recent survey indicated that 60% of Americans expressed worries about affording medications, with 40% reporting they had not taken prescribed medications due to cost. Joyce noted that consumers are more focused on their copay or out-of-pocket costs rather than the actual price of the drug.